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Abstract 
There has been considerable progress recently in the discovery and development of 
Keap1-interactive compounds that enhance Nrf2 transcriptional activity. The compounds 
fall into two broad classes: electrophilic cysteine-reactive compounds and non-
electrophilic Keap1-Nrf2 protein-protein interaction inhibitors. This short review highlights 
structures from both classes and discusses their development, biological properties and 
the future prospects for developing therapeutic agents. Molecules of both types have 
potential applications in areas including inflammatory conditions, chronic 
neurodegenerative diseases and possibly cancer chemoprevention. 
 
Introduction 
The activation of Nrf2 transcriptional activity has been highlighted as an attractive target 
for therapeutic intervention in a range of disease states spanning inflammatory and 
neurodegenerative conditions (including Parkinson’s disease and Alzheimer’s disease) 
and cancer chemoprevention [1]. Compounds that increase Nrf2 activity have therefore 
been sought as both chemical probes to evaluate the activity of Nrf2 in cells and as 
potential therapeutic agents. Most of the available compounds that increase Nrf2 activity 
do so by perturbing the behaviour of the ubiquitination facilitator protein Keap1 that targets 
Nrf2 for Cul3-mediated ubiquitination and destruction via a complex dynamic protein-
protein interaction (Figure 1). By stalling the ubiquitination process, the compounds 
increase the concentration of de novo synthesised Nrf2 within the cell and facilitate the 
expression of genes with Nrf2-responsive anti-oxidant response elements (AREs) in their 
promoter regions. In this review we will focus upon the two main groups of Keap1-
interactive small molecules that up-regulate Nrf2 activity: those that modify cysteine 
residues and those that interact reversibly with the Keap1 C-terminal Kelch domain. We 
will also comment on the future potential of this therapeutic approach. 
FIGURE 1.pptx 
Figure 1. A and B. Schematic representation of the closed (A) and open (B) forms of the 
Keap1-Nrf2 complex. C and D. Electrophilic inducers result in a closed form of the complex 
(C) and protein-protein interaction inhibitors an open form (D). Under resting conditions (A 
and B) Nrf2 is ubiquitinated (in form A) and free concentrations are kept at a low level. In the 
case of forms B, C, and D ubiquitination is stalled and Nrf2 accumulates in the cell and 
translocates to the nucleus [2, 3]. 
 
Electrophilic inducers 
Keap1 contains several cysteine residues in its BTB domain and intervening region that 
sense electrophilic and redox stress within the cell [4], and the first Nrf2 inducers to be 
identified were cysteine-interactive electrophilic or redox-active compounds with broad 
ranging biological activity [5]. By covalently modifying cysteine residues in Keap1, these 
compounds are able to stall the ubiquitination of Nrf2, apparently by inducing the formation 
of a closed non-functional form of the Keap1-Nrf2 complex (Figure 1C) [2, 6]. 
 
FIGURE 2.tiff 
Figure 2: A. Selected examples of electrophilic and pro-electrophilic Keap1 inhibitors; B. 
Modification of Keap1 cysteine thiols by Michael acceptors; C. Reaction of SFN with Keap1 
cysteine thiols. 
Electrophilic inducers have been described that are of natural, semisynthetic or synthetic 
origin (Figure 2A). Many are Michael acceptors that contain α,β-unsaturated carbonyl 
functionality and undergo 1,4-addition with reactive Keap1 cysteine thiols (Figure 2B) [5]. 
Examples include the recently approved drug for multiple sclerosis, dimethyl fumarate 1 
(Tecfidera®) [7], and the semisynthetic oleanolic acid derivative bardoxolone methyl 2 
(CDDO-Me), which has been evaluated in clinical trials for the treatment of chronic kidney 
disease, pulmonary arterial hypertension and cancer [8]. Although both 1 and 2 have been 
shown to induce accumulation and nuclear translocation of Nrf2 and subsequent activation 
of ARE-driven genes, their relative activities in vitro appear to differ considerably, with 2 
being one of the most potent Nrf2 inducers identified to date [9]. 
The Nrf2-inducing activity of 1 is dependent on the modification of Keap1 Cys151, while 
on the other hand structural analogues of 2 appear to maintain their activity in cells 
expressing mutant Cys151S Keap1 [10]. However, a co-crystal structure of 2 covalently 
bound to Keap1 Cys151 within the BTB domain of Keap1 was recently reported, raising 
the possibility of a functional interaction with this site [11]. 
Curcumin 3, a bis-Michael acceptor, is a further example of a reactive Nrf2 inducer [5] that 
exhibits both in vitro and in vivo activity [12, 13]. Despite its poor bioavailability, diverse 
biological activities and relatively low Nrf2-inducing potential [14], 3 has shown promising 
results in clinical trials for a plethora of different diseases [15]. tert-Butylhydroquinone 4 is 
an example  of a pro-Michael acceptor that is bio-activated to form tert-butyl-p-quinone 
[16], which can undergo Michael addition reactions with reactive thiol groups [17]. It 
interacts with Cys151 of Keap1 and in contrast to 2, its Nrf2-inducing activity is greatly 
impaired in Cys151S Keap1-expressing cells compared to wild-type cells [10]. 
One of the most well-characterised Keap1 electrophilic inhibitors is the isothiocyanate 
natural product sulforaphane 5, which is derived from its glucosinolate precursor 
glucoraphanin, found in cruciferous vegetables, including broccoli and Brussels sprouts 
[18]. Several Keap1 cysteine residues have been reported as targets of 5 (Figure 2C) [19], 
however, its activity is highly dependent on Cys151 both in vitro [20] and in vivo [21]. 5 is 
able to induce the nuclear accumulation of Nrf2 and subsequent transcription of its 
associated genes at mid-high nanomolar concentrations, exerting protective effects 
against inflammation and oxidative stress as well as reducing cancer cell proliferation and 
viability [18]. In addition, it has been evaluated in animal models and clinical trials for a 
plethora of diseases and degenerative conditions, including but not limited to several 
cancer types, diabetes and neurodegenerative conditions [18, 22-25]. 
Despite the interesting cellular activity of the various electrophilic inducers and their 
adoption as chemical probes to investigate Nrf2 in cellular processes and disease models 
[26], their reactive nature is problematic, resulting in a range of off-target effects [27]. 5 in 
particular has been shown to interact directly with a variety of redox-sensitive targets [28], 
leading to a complicated mode of action and several Nrf2-independent effects [29-32]. 
Molecules with a higher selectivity for Keap1 could exhibit lower toxicity and have a better 
therapeutic profile, while in addition they would be more attractive chemical tools to probe 
the complex biology associated with the Keap1/Nrf2 pathway. In this respect the chemical 
properties of 2 are particularly interesting, because its cyano-enone moiety undergoes a 
reversible Michael-type reaction with cysteine residues. This raises the prospect of limiting 
off-target effects, because the reaction with cysteine residues is reversible, but promoting 
Keap1 interaction via complementary non-covalent interactions at the Keap1 binding site.  
 
Direct (non-covalent) Nrf2 inducers 
Despite the interesting biological activity of electrophilic Nrf2 inducers, direct non-covalent 
inhibition of the Keap1-Nrf2 protein-protein interaction (PPI) has been proposed as an 
alternative, more selective approach to increase Nrf2 activity [5, 27, 33]. Crystallographic 
(Figure 3B) and mutagenesis studies have shown that Nrf2 binds to Keap1 through 
relatively short sequences to a well-defined pocket within the Keap1 Kelch domain and 
this interaction is mediated mainly by the acidic residues of the ETGE and DLG Nrf2 motifs 
[34-36]. The interacting surface area between Keap1 and Nrf2 is relatively small and 
resembles a receptor-type interaction rather than a typical PPI, suggesting that the 
discovery of potent PPI inhibitors is possible [33]. 
A number of peptide ligands have been designed and evaluated [37-39]. Those based 
upon hybrid sequences derived from the high affinity Nrf2 (ETGE) binding sequence and 
the related p62 Keap1 interaction region yielded a high affinity 7mer peptide, Ac-
DPETGEL-OH (IC50 = 116 nM) [38] a related 11mer peptide, Ac-CLDPETGEYLC-OH had 
a slightly higher affinity (Kd = 15.9 nM) [39]. The cell permeability of these acidic peptides 
is quite poor although efforts to improve their biological activity through fatty acid [40] or 
TAT peptide conjugation [41] have had some success, generally yielding molecules with 
micromolar activity in Nrf2-dependent enzyme expression assays (NQO1 and HO1 
respectively). 
 
Small molecules 
Following the success of peptide inhibitors of the Keap1-Nrf2 PPI in vitro several groups 
pursued small molecules that activate Nrf2 via this same mode of action (Figure 3A) [33]. 
Most of the initial hit compounds were identified using high-throughput screening 
approaches although rational design, fragment-based approaches and in silico methods 
have been used in recent discovery and lead optimisation studies. 
 FIGURE 3A.tiff 
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Figure 3. A. Selected examples of small molecule Keap1-Nrf2 PPI inhibitors; B. Crystal 
structure of an Nrf2 ETGE peptide bound to Keap1 (Nrf2 ETGE residues displayed) (PDB: 
2FLU); C. Crystal structure of 10 bound to Keap1 (PDB: 4XMB); D. Crystal structure of 13 
bound to Keap1 (PDB: 5FNU). The Keap1 Kelch domain is shown as a surface 
representation, peptides and small molecules in stick representation. 
The first small molecule inhibitor to be described was the tetrahydroisoquinoline LH601A 
6 [42], a compound originally identified as an HTS hit from the MLPCN screening library 
(337,116 compounds). The (S,R,S) configuration of 6 was optimal for Keap1 binding (Kd 
= 1.0 µM, fluorescence polarisation assay) and it induced the nuclear translocation of Nrf2 
in cells with an EC50 of 12 µM [42]. The compound up-regulated NQO1, HO-1 and TRX1 
at mid-high micromolar concentrations in HEK293 cells but had limited effect on 
glutathione-related genes [43]. Interestingly, in the same study, sulforaphane 5 enhanced 
levels of GCLC (glutamate cysteine ligase, catalytic), GCLM (glutamate cysteine ligase, 
modifier) and GSR (glutathione reductase) in addition to NQO1, HO-1 and TRX1. 
Structural insights into the binding behaviour of 6 were obtained from a co-crystal structure 
with Keap1, but significant improvements in binding affinity were difficult to achieve [44]. 
An analysis of the DMPK properties of 6 showed that it was restricted to the peripheral 
compartment, due in part to it being a P-gp substrate. Attempts were made to obtain in 
vivo brain exposure, but binding affinity was lost [44].  
Two sulphonamide compounds were identified through an HTS screen conducted using 
the Evotec Lead Discovery library (267,551 compounds) supplemented with 1,911 
compounds, previously identified by virtual screening [45]. The benzenesulfonyl 
pyrimidone 7 and the symmetrical naphthalene bis-sulfonamide 8 had IC50 values of 118 
µM and 2.7 µM respectively in a confocal fluorescence anisotropy assay. Compound 8 
stabilised Nrf2 and up-regulated NQO1 expression at low-mid micromolar concentrations 
[45]. Attachment of acetate side chains to the sulfonamide nitrogen atoms of 8 had a 
profound effect on the overall activity of the compound series, yielding a symmetrical bis-
acid 9 with an IC50 of 28.6 nM [46]. Molecular docking simulations demonstrated that the 
acetic acid moieties mimic the two glutamate side chains of the high-affinity ETGE motif 
of Nrf2 and interact with Arg483 and Arg415 in the Keap1 binding pocket.  Co-
crystallisation of a related bis-acetamide compound 10 confirmed the proposed binding 
mode (Figure 3C) [47]. Despite the presence of two ionisable groups, 9 was able to 
activate the expression of Nrf2-dependent gene products at low µM concentrations [46]. 
A follow-up study revealed that a p-acetamido analogue of 11 had improved solubility and 
cellular activity in an Nrf2-dependent ARE luciferase assay at concentrations as low as 
100 nM. In vivo a dose of 10 mg/kg was sufficient to reduce the levels of inflammatory 
markers in an LPS-induced inflammation model without exhibiting acute toxicity (Table 1) 
[48].  
The bis-sulfonamide structure has been de-symmetrised in several studies [47, 49], one 
of which resulted in RA839, 12 which inhibited the Keap1-Nrf2 PPI with an FP IC50 of 140 
nM and an ITC Kd of 6 µM. The compound had promising cell-based activity, but was 
found to be subject to oxidative metabolism, which hampered in vivo evaluation [49]. 
Cpd Keap1 
KD (ITC) 
Disease 
model 
Treatment Disease 
relevance 
Outcome Ref 
6 39.8 nM LPS-induced 
model of 
inflammation 
(mouse) 
10 mg/kg/day or 
80 mg/kg/day 
for 3 days 
before LPS 
challenge 
Inflammatory 
conditions 
Prophylactic treatment 
relieves LPS-induced 
inflammation: 
↓ cytokine levels (TNF-α, 
IFN-γ, IL-6, IL-12, IL-17) 
[48] 
6 39.8 nM DSS-induced 
model of UC 
(mouse) 
10 mg/kg or 40 
mg/kg (oral) 
simultaneous 
administration  
with 3% w/v 
DSS 8 days on 
8 days off (x4 
cycles) 
UC, Crohn’s 
disease, 
inflammatory 
bowel 
disease, 
colorectal 
cancer 
Protects against DSS-
induced damage: 
elimination of inflammatory 
cells, preserved colonic 
structure, prevented of 
lamina propria expansion, ↑ 
colonic GSH:GSSG ratio 
[50] 
8 1.3 nM Ozone (O3)-
induced rat 
model of 
pulmonary 
inflammation 
16.5 mg/kg (iv) 
for 6 hours 24 
hours before 
ozone injury: 1 
ppm for 3 hours. 
COPD Attenuation of pulmonary 
inflammation: ↓ levels of 
inflammatory cells in the 
bronchoalveolar fluid, 
preserved levels of GSH, ↓ 
oxidative stress 
[51] 
10 NA CDDA rat 
model of 
NASH 
6 weeks pre-
feeding of 
CDAA diet 
followed by 4 
weeks 60 
mg/kg/day 
administration 
NASH Treatment prevented 
progression of established 
fibrosis in NASH model rats 
liver: ↓ fibrosis score, ↓ % 
fibrosis area 
[52] 
Table 1: In vivo disease model studies with Keap1-Nrf2 protein-protein interaction inhibitors. 
Notes: NA – data not available; LPS – lipopolysaccharide; DSS – dextran sodium sulfate; 
UC – ulcerative colitis; COPD – chronic obstructive pulmonary disease; CDDA – choline 
deficient, L-amino acid defined; NASH – non-alcoholic steatohepatitis. 
 
Recently, Astex and GSK identified a high affinity lead compound through a 
crystallographic fragment-based screen. Linkage of three fragments with orthogonal 
Keap1 binding behaviour followed by SAR-based optimisation yielded the mono acid 13 
(Kd 1.3 nM) (Figure 3D). The compound induced the expression of a range of Nrf2 target 
genes (NQO1, HO1, glutamate-cysteine ligase, thioredoxin reductase-1) at low nanomolar 
concentrations. Subsequently the compound was shown to exert protective effects in an 
in vivo COPD model (Table 1) [51]. 
A further compound to emerge from Toray Industries was the urea derivative 14 [53]. 
Although its binding affinity for Keap1 has not been described, it has been co-crystallised 
with the Keap1 Kelch domain. The related pyridine derivative 15, although a relatively 
weak Keap1 ligand (Keap1-Nrf2 PPI inhibition > 50 µM), exerts protective effects in a rat 
model of non-alcoholic steatohepatitis (Table 1) [52].  
Amongst the non-electrophilic Nrf2 inducers a class of 1,4-diphenyl-1,2,3-triazoles has 
been studied in detail with regard to their effects on cellular functions associated with 
mitochondrial autophagy (mitophagy) and Parkinson’s disease. Prototype compounds 
such as 16 and 17 inhibit the Keap1-Nrf2 interaction in live cells and increase the 
expression of Nrf2 target genes [3]. A direct comparison between 17 and sulforaphane 5 
indicated differences in cellular effects between the two types of inducer. In particular, 17 
was able to promote mitophagy without an apparent effect on mitochondrial membrane 
potential or function, an activity that was partially independent of the PINK1/Parkin 
mitophagy pathway [54, 55]. 5 was less able to induce these effects, suggesting that there 
may be different therapeutic applications for non-electrophilic ligands, particularly in the 
area of Parkinson’s disease where PINK1 and Parkin play a role in hereditary and early 
onset forms of the condition [56]. 
 
Future perspectives 
There has been considerable recent progress in the development of compounds that 
induce Nrf2 activity for potential therapeutic applications. The high-potency bardoxolone 
methyl-type inducers are examples of promising electrophilic compounds with an 
intriguing reversible covalent binding mode. They have shown therapeutic efficacy in a 
range of disease settings although their therapeutic window and toxicities need further 
research after their recent failure in a phase 3 clinical study for chronic kidney disease 
[57]. Reversible inhibitors of the Keap1-Nrf2 PPI have been developed recently. Despite 
the difficulty of targeting protein-protein interactions, several structural classes of inhibitors 
have been identified that bind to Keap1 with high affinity. The potential for these 
compounds to exert different effects of Nrf2, both in magnitude and timescale, and 
different pharmacological effects on treated cells suggests that they may have a different 
range of therapeutic applications, particularly in the area of neurodegenerative diseases. 
However, in order to progress to in vivo studies for CNS applications the current pool of 
lead compounds will require further optimisation in order to achieve the physicochemical 
properties required for crossing the blood-brain barrier. 
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